To tie in with the University’s strategy to strengthen research in health as set out in Vision 2020, CCIR will continue to focus its expertise and resources on research in its niche areas which will generate the greatest possible results and impact. The Centre’s efforts are currently focused on the following three major areas:
I) Basic science research
In this research area, we will focus on:
i. | Molecular cancer biology and carcinogenesis of colorectal cancer, ovarian cancer, melanoma and liver cancers; |
ii. | Metastatic cancer biology of the aforementioned cancers; and |
iii. | Chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel diseases. |
II) Translational science/medicine research
Our work in this area will be focused on treating cancer and inflammatory diseases by means of:
i. | Chinese medicine; |
ii. | Targeted therapies, including among others immunotherapy; and |
iii. | Development of different drug delivery methods. |
III) Clinical research
Our work in this area will be focused on:
i. | Design clinical trial protocols based on the confirmed experimental animal data and research findings of qualified Chinese pharmaceutical products, and evaluate their clinical therapeutic efficacy in treating rheumatoid arthritis; |
ii. | Conduct epidemiological and clinical studies for evaluating the clinical therapeutic efficacy of using herbal medicine alone or in combination with chemotherapy and radiotherapy in treating lung cancer, and of using herbal medicine in treating rheumatoid arthritis etc.; |
iii. | Establish a tissue samples library for the common cancerous and inflammatory diseases in Hong Kong such as lung cancer, colorectal cancer, mammary carcinoma, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, etc. |
With our strong research teams, combined expertise and well-defined focuses in basic and translational science, we are confident of achieving breakthrough results in the foreseeable future.